FDA Releases CMC Postapproval Manufacturing Changes For Specified Biological Products To Be Documented In Annual Reports
This new FDA/CDER guidance represents the FDA's thinking regarding the types of changes to an approved biologics license application (BLA) that...
Mark Durivage Office Of Communication International Council For Harmonisation Office Of Pharmaceutical Quality Quality Systems Compliance Drug Evaluation
Source: lifescienceleader.com